Protecting Patients from Deceptive Drug Ads Act

S 652 requires social media influencers and healthcare providers to avoid false or misleading promotions of FDA-approved drugs on social media, including disclosing key safety information like side effects in a summary format similar to traditional drug ads. It makes these individuals liable for civil penalties if they knowingly or recklessly omit critical facts or fail to include required safety summaries. The bill also directs the FDA to issue new guidance on enforcement, monitor drug ads using AI, and conduct market surveillance on social media platforms. This affects influencers, healthcare providers, and drug manufacturers who pay for such promotions, with the FDA authorized to spend $15 million annually for enforcement.